Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bortezomib - Takeda Oncology

Next Previous
Drug Profile

Bortezomib - Takeda Oncology

Alternative Names: JNJ-26866138; LDP-341; MG-341; MLN-341; NSC-681239; PS 0341; PS-341; Velcade

Latest Information Update: 29 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Millennium Pharmaceuticals
  • Developer Bayer; Celgene Corporation; Childrens Mercy Hospital Kansas City; Dana-Farber Cancer Institute; Duke University; Erasmus MC; Genentech; Hoosier Cancer Research Network; HOVON Foundation; Indiana University; Janssen Pharmaceutical KK; Janssen Research & Development; Janssen-Cilag; Johnson & Johnson; Memorial Sloan-Kettering Cancer Center; Merck Sharp & Dohme; Millennium; Millennium Pharmaceuticals; Singapore General Hospital; Takeda Oncology; University of Michigan Comprehensive Cancer Center; Weill Cornell Medical College; Xian-Janssen
  • Class Amides; Anti-ischaemics; Antineoplastics; Antirheumatics; Boronic acids; Pyrazines; Small molecules; Vascular disorder therapies
  • Mechanism of Action Apoptosis stimulants; NF-kappa B inhibitors; Proteasome inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mantle-cell lymphoma; Multiple myeloma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Mantle-cell lymphoma; Multiple myeloma; Waldenstrom's macroglobulinaemia
  • Registered B-cell lymphoma
  • Phase III Diffuse large B cell lymphoma
  • Phase II Amyloid light-chain amyloidosis; Glioma; Graft-versus-host disease; Hodgkin's disease; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Peripheral T-cell lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
  • Phase I/II Acute myeloid leukaemia
  • Preregistration Submission Withdrawal Follicular lymphoma
  • No development reported Malignant melanoma; Neuroblastoma; Pancreatic cancer
  • Discontinued Adenocarcinoma; Cerebral ischaemia; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Prostate cancer; Rheumatoid arthritis; T-cell prolymphocytic leukaemia

Most Recent Events

  • 09 Dec 2023 Efficacy and adverse events data from a phase-III clinical trials in Multiple myeloma presented at the 65th American Society of Hematology Annual Meeting and Exposition(ASH-Hem-2023)
  • 10 Dec 2022 Efficacy and adverse events data from a phase II trial in Amyloidosis presented at the 64th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2022)
  • 20 Sep 2022 Phase-III clinical trials in Multiple myeloma (Combination therapy, Second-line therapy or greater) in USA (IV) (NCT05519085)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top